Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc. today is presenting data from an open-label extension of its Phase IIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD) at the Alzheimer's Association's International Conference on Prevention of Dementia in Washington, D.C. Consistent with the findings of earlier clinical and preclinical studies, AC-1202 was shown to be safe and to significantly improve the memory and cognition of subjects of a particular pharmacogenomic profile.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD at 25 centers across the United States. AC-1202 was administered once daily, and most patients continued to take their other AD drugs such as acetylcholinesterase inhibitors. Following three months of treatment and a two-week washout, eligible subjects were given the opportunity to receive AC- 1202 in a six-month open-label extension study. The main clinical outcome for efficacy was improvement in the AD Assessment Scale-Cognitive (ADAS-Cog) score, which measures memory and other aspects of cognitive performance.

In the double-blind phase of the clinical study the ADAS-Cog scores of the AC-1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01) compared to the placebo group, and statistically significant improvement was seen in just 45 days. ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5-point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease.

As in the double-blind phase of the study, the most profound effect was seen in subjects not expressing the ApoE4 genotype, a genetic risk factor for AD. ApoE4(-) subjects represent the other half of Alzheimer's patients. ApoE4(-) subjects who started taking AC-1202 on the open-label e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans ... OxyContin is a serious public health and safety issue in ... from a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication ... progress with this very serious health situation facing our country," ...
(Date:8/21/2014)... August 21, 2014 BreedIT ... Ltd., the exclusive worldwide license holder and distributor ... breeders and researchers, today is pleased to announce ... with Seach Ltd, a leading Israeli medical Cannabis ... and develop new breeds of medical Cannabis to ...
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2
... Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical,company Pharmaxis (ASX: PXS; ... positive,results of its recently completed international Phase III trial ... represents one of,the largest clinical trials conducted in cystic ... of the trial was to assess whether Bronchitol,improves lung ...
... Va., May 1 C. Larry Pope, President and ... SFD ), sent the following update to all ... at its joint venture operation in Veracruz:To Our Employees:The ... on a minute-to-minute basis, and while we would like ...
Cached Medicine Technology:Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 2Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 4Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 5Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture 2
(Date:8/23/2014)... August 23, 2014 Peripheral intervention surgeries ... remove plaques, etc, thereby addressing the root cause of ... of blood to the other part of the arteries ... blood. These procedures require the use of a catheter, ... and polymers), these catheters are inserted through a thin ...
(Date:8/23/2014)... 2014 Hundreds of Wright hip ... of individuals who were allegedly harmed by devices ... to move forward in the U.S. District Court, ... According to an Order dated August 19th, the ... would allow the litigation’s first case to go ...
(Date:8/23/2014)... Professional kitchen employees, prospective chefs and ... preparing for Food Safety Certification exams thanks to the ... Path. , Dynamic Path announced the release of its ... 200 review questions for culinary industry students and professionals. ... requirements of the ServSafe® Food Safety Certification, National Registry ...
(Date:8/23/2014)... Teen drug and alcohol abuse is a major ... NC. Substance abuse can happen to people of all ... alcohol dependency in higher numbers than ever before. ... but don’t know where to find professional youth rehab. ... challenge because most treatment options are designed for adults. ...
(Date:8/22/2014)... Texas (PRWEB) August 23, 2014 ... Industry” is a professional and in-depth research report ... basic Glucose Meter information, including Glucose Meter definition, ... as industry overview. This research covers the international ... global industry analysis covering macroeconomic environment & economic ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3
... in endurance sports, study finds , THURSDAY, June ... to strengthen inhalation muscles and reduce their need ... such as cycling and swimming, a new study ... muscle training (IMT) significantly reduced the amount of ...
... ... Between Sharks and Surfers. , ... (PRWEB) June 3, 2010 -- Surfline thinks it takes more than a week to explain ... in the presence and environment of sharks as surfers. Therefore, Surfline has launched "Shark Month" ...
... what it would be like to go on a mission ... will enter an isolation chamber in Moscow for a simulated ... the Russian Federation Institute for Biomedical Problems (IBMP) of ... schedule full of more than 90 experiments and realistic scenarios, ...
... Study ... ... -- Chemotherapy-induced amenorrhea in premenopausal women being treated for early stage breast cancer was ... the New England Journal of Medicine by the National Surgical Adjuvant Breast and Bowel ...
... Le Cordon ... worldwide “Apéritif à la Française" on June 3rd, 2010 at the Espace Réunion in Montreal, ... ... Ottawa Culinary Arts Institute is proud to announce that it will be one of the ...
... ... for Medical Marijuana Hydroponics Nutrients , ... Seattle, WA (PRWEB) June 3, 2010 -- In a landmark decision, ... hydroponics nutrients., , ,Oregon and most other states have regulatory agencies that ...
Cached Medicine News:Health News:Surfline Launches "Shark Month" Presented by Casio G'zOne 2Health News:520-day Mars mission simulation 2Health News:520-day Mars mission simulation 3Health News:520-day Mars mission simulation 4Health News:Interruption of Menstrual Cycle by Chemotherapy Associated with Improved Survival in Early Breast Cancer 2Health News:Interruption of Menstrual Cycle by Chemotherapy Associated with Improved Survival in Early Breast Cancer 3Health News:Interruption of Menstrual Cycle by Chemotherapy Associated with Improved Survival in Early Breast Cancer 4Health News:Le Cordon Bleu Ottawa to Sponsor Apritif la Franaise in Partnership with Sopexa 2Health News:Hydroponics Nutrients For Medical Marijuana Gain Government Approval 2
... cost-effective line of compact CO2 systems available ... 30 or 40 watts combines portability ... extremely accurate laser beam, as well as ... advantageous for small operating theatres and are ...
... Applications include PhotoLightFACIAL facial skin ... vein removal. Incorporates a ... to 1200nm), multiple hand pieces ... give you the most flexibility. ...
... delivered through an ultra thin flexible 400 - ... freedom of movement when performing surgery. The ... range of handpieces. Handpieces are supplied with ... mm. Straight and angled fiber guides with ...
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
Medicine Products: